Department of Urology, Tulane University School of Medicine, 1430 Tulane Ave. 86-42, New Orleans, LA, 70112, USA.
Curr Urol Rep. 2021 Jan 8;22(2):6. doi: 10.1007/s11934-020-01024-8.
To analyze the literature on current conservative treatment options for Peyronie's disease (PD).
Conservative therapy with intralesional collagenase clostridium histolyticum (CCH) is safe and efficacious in either the acute or chronic phases of PD. Combination treatment with penile traction therapy (PTT) can produce even better results. While most PTT devices require extended periods of therapy up to 8 h per day, the RestoreX® device can be effective at 30-90 min per day. A variety of conservative therapies are available for treatment of PD. The available literature does not reveal any treatment benefit of oral therapies. Intralesional therapy is the mainstay conservative treatment of PD. Intralesional CCH therapy is the first Food and Drug Administration-approved intralesional therapy and represents the authors' preference for medical therapy. The most effective conservative management of PD likely requires a combination of therapies.
分析目前治疗 Peyronie 病(PD)的保守治疗选择的文献。
对于 PD 的急性或慢性阶段,腔内注射胶原酶 clostridium histolyticum(CCH)的保守治疗安全且有效。与阴茎牵引疗法(PTT)联合治疗可以产生更好的效果。虽然大多数 PTT 设备需要长时间治疗,每天长达 8 小时,但 RestoreX®设备每天 30-90 分钟即可有效。有多种保守疗法可用于治疗 PD。现有文献并未显示任何口服疗法的治疗益处。腔内治疗是 PD 的主要保守治疗方法。腔内注射 CCH 治疗是首个获得食品和药物管理局批准的腔内治疗方法,也是作者对药物治疗的偏好。PD 的最有效保守治疗可能需要联合治疗。